News Center
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
Kintor Pharmaceutical Receives Emergency Use Authorization for Proxalutamide for the Treatment of COVID-19 in Paraguay
(Summary description)Suzhou, July 16, 2021 - Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that Paraguay’s Ministry of Public Health and Social Welfare (MSPBS) has granted an emergency use authorization (EUA) for proxalutamide to treat hospitalized patients with COVID-19 infections at the MSPBS hospitals.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2021-07-16 13:16
- Views:
Suzhou, July 16, 2021 - Kintor Pharmaceutical Limited (HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that Paraguay’s Ministry of Public Health and Social Welfare (MSPBS) has granted an emergency use authorization (EUA) for proxalutamide to treat hospitalized patients with COVID-19 infections at the MSPBS hospitals.
The first hospital to use proxalutamide under the EUA, Hospital Barrio Obrero, part of Paraguay’s MSPBS network, has reported promising initial results. Of the first 25 COVID-19 inpatients treated with Proxaluatmide, only 1 patient (4%) died. Such mortality rate was lower than the usual mortality rate of COVID-19 patients in Paraguay. In addition, proxalutamide has demonstratd potential benefits in 7 of the patients who initially required high flow oxygen.
Dr. Youzhi Tong, the founder, Chairman, and CEO of Kintor Pharmaceutical, commented, "We are delighted to see that proxalutamide is saving lives in Paraguay following the EUA from the MSPBS. We are actively exploring additional EUAs of proxalutamide in other countries and regions to help COVID-19 patients around the world."
Business
News Center
Contact Us
Find Us


Copyright: Kintor Pharmaceutical Limited retains all copyrights. 苏ICP备19028699号-2 Powered by 300.cn
Complaints and Suggestions Tel: +86 512 62639935 Email: public@kintor.com.cn